4月17日,礼来制药公布旗下口服GLP-1(胰高血糖素样肽-1)制剂“Orforglipron”的临床数据,在最高剂量下,每日服用一次Orforglipron的患者实现了平均减重7.3kg(7.9%)。这一表现超过了礼来之前预计的减重范围。 礼来方面预计,Orforglipron有望于今年底前向全球监管机构提交用于体重管理的上市申请,预计于2026年提交其用于治疗2型糖尿病的上市申请。 4月...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.